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Pulmonary function measures predict
mortality differently in IPF versus combined
pulmonary fibrosis and emphysema
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ABSTRACT: The composite physiologic index (CPI) was derived to represent the extent of
fibrosis on high-resolution computed tomography (HRCT), adjusting for emphysema in patients
with idiopathic pulmonary fibrosis (IPF). We hypothesised that longitudinal change in CPI would
better predict mortality than forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) or
diffusing capacity of the lung for carbon monoxide (DL,CO) in all patients with IPF, and especially
in those with combined pulmonary fibrosis and emphysema (CPFE).
Cox proportional hazard models were performed on pulmonary function data from IPF patients at
baseline (n5321), 6 months (n5211) and 12 months (n5144). Presence of CPFE was determined by
HRCT.
A five-point increase in CPI over 12 months predicted subsequent mortality (HR 2.1, p50.004). At
12 months, a 10% relative decline in FVC, a 15% relative decline in DL,CO or an absolute increase in
CPI of five points all discriminated median survival by 2.1 to 2.2 yrs versus patients with lesser
change. Half our cohort had CPFE. In patients with moderate/severe emphysema, only a 10%
decline in FEV1 predicted mortality (HR 3.7, p50.046).
In IPF, a five-point increase in CPI over 12 months predicts mortality similarly to relative
declines of 10% in FVC or 15% in DL,CO. For CPFE patients, change in FEV1 was the best predictor
of mortality.
KEYWORDS: Chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, prognosis,
pulmonary function, survival
I
diopathic pulmonary fibrosis (IPF) is a
progressive, fatal diffuse parenchymal lung
disease [1–4]. Progression of disease is het-
erogeneous. Some patients decline rapidly, others
remain stable and all appear at risk of developing
acute exacerbations [2, 3, 5]. Methods to assess
and monitor disease status and ultimately predict
mortality and response to therapy are needed.
A variety of variables including pulmonary func-
tion at time of diagnosis, hypoxaemia at rest,
desaturation during a 6-min walk test, long-
itudinal changes in forced vital capacity (FVC),
longitudinal changes in diffusing capacity of the
lung for carbon monoxide (DL,CO) and perform-
ance on cardiopulmonary exercise testing have
been shown to have prognostic value [6–12].
Smoking is a common risk factor for both
emphysema and pulmonary fibrosis [13–15].
Therefore, patients with IPF may have combined
pulmonary fibrosis and emphysema (CPFE). The
presence of both pathologies could limit the
ability to utilise FVC in the assessment and
monitoring of disease course [16, 17]. The com-
posite physiologic index (CPI) was developed to
improve on previous prognostic measures in IPF
by adjusting for emphysema and incorporating
multiple measures of pulmonary function,
namely forced expiratory volume in 1 s (FEV1),
FVC and DL,CO [18]. The CPI score at diagnosis
more accurately predicted mortality than the
individual pulmonary function tests (PFTs) alone
in patients with concomitant emphysema [18].
We hypothesised that longitudinal changes in
CPI would more accurately predict mortality
than previously published longitudinal declines
in FVC of 10% and DL,CO of 15% in all patients
with IPF, and to a greater degree in patients with
CPFE [7–10]. As such, we tested the CPI in a large
cohort of patients diagnosed with IPF on bio-
psy or high-resolution computed tomography
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(HRCT). We evaluated the magnitude of CPI change required
to predict an increased risk of mortality, and compared the
relevant longitudinal change in CPI with changes in individual
PFTs. Finally, we evaluated if the presence/absence of emphy-
sema impacted the ability of CPI or individual measures of
pulmonary function to predict mortality.
MATERIALS AND METHODS
Study population
Patients with IPF were selected from the University of
Michigan (Ann Arbor, MI, USA) interstitial lung disease
database. The diagnosis of IPF was made with either a surgical
lung biopsy or HRCT scan diagnostic of usual interstitial
pneumonia (UIP) using standard criteria [1, 3, 4, 7]. Patients
were included if they had a PFT performed at the University of
Michigan within 3 months of diagnosis. Mortality data were
confirmed through the Social Security Death Registry Index
censured by 3 months to account for reporting lag. Follow-up
time was calculated from date of baseline PFT to date of death
or censure. IPF patients were eligible for the analysis of CPFE if
a HRCT had been performed at the University of Michigan
within 1 yr before or after diagnosis.
Methods
Patients with at least one additional PFT after baseline were
eligible for longitudinal analyses. For the 6-month analysis, all
PFTs from 3 to 9 months after the baseline study were included
to generate a regression line for each patient. An estimated
6-month PFT value was obtained from the regression. At least
one PFT performed between 9 and 15 months after diagno-
sis was required to be included in the 12-month analysis. The
same individual regression technique was used for 12-month
data using all PFTs up to 15 months after baseline. The CPI
was calculated from the following formula: 91 – (0.65x%
predicted DL,CO) – (0.53x% pred FVC) + (0.34x % pred FEV1)
[18]. Relative changes in PFT values were calculated as the
estimated 6 or 12 month value minus the baseline value,
divided by the baseline value.
The index of concordance (IOC) was used to compare
predictive ability of the longitudinal change in various PFTs
and CPI [19]. The IOC analysis considers each combination of
two patients in the dataset and measures how accurately the
model predicts which patient will live longer. The higher the
IOC, the more likely the variables in the model explain the
outcome, in this case mortality. Various cut-off points of
relative and absolute change in CPI were studied to determine
what change of CPI would yield the best IOC.
Emphysema was scored semi-quantitatively as none, mild
(present but scant), moderate (notable or equivalent in extent
to the fibrosis) or severe (the predominant pathology) by a
thoracic radiologist experienced with HRCT scoring in prior
clinical trials, blinded to tobacco history and patient out-
come. Figure 1 contains representative images. Patients were
grouped together for analysis as none/mild or moderate/
severe emphysema.
Survival analysis
Cox proportional hazards models adjusting for age at diag-
nosis, sex and smoking status were used to assess the rela-
tionship of FEV1, FVC, DL,CO and CPI to mortality [20].
Longitudinal models included adjustment for baseline PFT
value. Time zero for median survival calculations was the last
PFT, either 6 or 12 months. Therefore, the survival only applies
to patients who were able to provide a 6 or 12 month PFT.
Longitudinal changes in CPI were compared with longitudinal
changes in each of its PFT components, including the pre-
viously published relative declines in FVC (10%) and DL,CO
(15%) [7–10]. We also evaluated changes in CPI and PFTs
in patients stratified by amount of emphysema. All statistics
were performed on SAS1 9.2 software (SAS Institute Inc.,
Cary, NC, USA). Our institutional review board approved the
study. Data on a subgroup of this patient cohort has been
previously published [7, 9]. A portion of these results was
presented at the 2010 American Thoracic Society International
Conference [21].
RESULTS
Patient population
We identified 396 patients with IPF from 1995 to 2007. Of these,
321 patients had a baseline PFT performed at the University of
Michigan, 211 patients had 6-month data and 144 had
12-month data. Of the 99 who did not have any longitudinal
data, 34 died. 15 of the 67 who had 6-month but not 12-month
data died. The remainder returned to the community for
continuity of care. HRCT performed at the University of
Michigan was available for analysis in 169 and 118 from the
6- and 12-month patients cohorts, respectively. Baseline demo-
graphics were not clinically different between patients parti-
cipating in the baseline 6 or 12 month analyses or between
patients with or without a HRCT available for scoring of em-
physema, table 1.
Comparison at baseline
We assessed the impact of the baseline CPI and each indivi-
dual component (FEV1, FVC and DL,CO) on risk of subsequent
mortality. Each component, as well as the CPI, was predictive
of subsequent mortality with all measures showing increased
risk of mortality with greater physiological derangement
(table 2). A lower DL,CO was associated with greater risk of
mortality compared with similar degrees of dysfunction in
FEV1 or FVC.
Identifying relevant longitudinal change in CPI
We used IOC to compare the ability to predict mortality from
longitudinal changes in CPI and the individual measures of
pulmonary function. An absolute increase of five points in the
CPI at 6 months yielded the highest IOC of 0.664, therefore the
model would correctly predict patients at an increased risk of
mortality 66.4% of the time. At 12 months, an absolute increase
of 15 points had the highest IOC of 0.690 but only 6% of the
cohort achieved this extent of worsening and an absolute
increase in five points was within 1.2%, IOC of 0.678. There-
fore, we determined an absolute increase of five points to be a
clinically meaningful longitudinal change for future analyses.
By comparison, a relative decline in FVC of 10% and DL,CO of
15% at 12 months yielded IOCs of 0.689 and 0.683 respectively,
all roughly equivalent.
Longitudinal change and survival
Cox proportional hazards models of mortality with varying
longitudinal changes in CPI, FEV1, FVC and DL,CO over 6 and
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12 months are shown in table 3. At 6 months, only change in
DL,CO was consistently significant. The other PFTs and the CPI
exhibited variable significance and in general were insigni-
ficant at greater perturbations from baseline. This may repre-
sent the inherent variability in these physiological measures
over short time periods. At 12 months, the models became
more consistent as one would expect. The relative FVC decline
of 10% and DL,CO decline of 15% yielded similar hazard ratios
(HRs) at 2.4 and 2.3, respectively, with p-values ,0.001. An
increase in CPI of five points was similar with a HR of 2.1. An
increase in CPI of 20 points yielded the highest HR at 5.2, but
only applied to two patients. A CPI increase of five points was
still significant after removing those patients with an increase
in CPI .15 (HR 1.9; 95% CI 1.1–3.2, p50.017).
Survival curves based on 12-month PFT and CPI data are shown
in figure 2a–d. CPI performed similarly to its components FEV1,
FVC and DL,CO. Median survival (95% CI), from the date of the
last PFT for a five-point increase in CPI over 12 months was
2.63 yrs (1.63–3.93) compared with 4.75 yrs (3.53–6.81) for a less
than five point change. This was similar to a 15% relative decline
in DL,CO, 2.58 yrs (1.63–3.57) versus 4.75 yrs (3.74–6.81).
Longitudinal changes in all physiological variables discrimi-
nated median survival in this patient population by 2 to 2.2 yrs.
a) b) c) d)
FIGURE 1. Examples of the high-resolution computed tomography scan semi-quantitative scoring system. Each panel contains a characteristic upper and lower lobe
slice of a patient scored as a) none, b) mild, c) moderate and d) severe emphysema.
TABLE 1 Baseline demographics and pulmonary function data
Baseline 6 month 6 month HRCT 12 month 12 month HRCT
Patients n 321 211 169 144 118
Age at diagnosis yrs 63.9¡9.7 63.2¡10.0 63.8¡9.8 62.3¡10.0 62.7¡10.0
Male 217 (67.6) 151 (71.6) 127 (75.1) 102 (70.8) 88 (74.6)
Ever tobacco use 236 (73.5) 162 (76.8) 131 (77.5) 109 (75.7) 89 (75.4)
Tobacco pack-yrs 26.2¡27.5 27.2¡28.4 27.2¡28.0 26.6¡27.6 27.3¡28.1
Surgical lung biopsy 245 (76.3) 158 (74.9) 118 (69.8) 113 (78.5) 88 (74.6)
Follow-up yrs 5.2 (4.9–6.1) 5.4 (5.1–7.0) 5.1 (4.7–6.1) 6.6 (5.3–7.7) 5.4 (5.0–7.0)
Pulmonary function
FEV1 % pred 79.2¡19.0 79.1¡17.2 79.1¡17.0 80.7¡18.6 80.9¡18.5
FVC % pred 67.6¡16.8 68.0¡15.8 67.7¡15.3 69.0¡16.4 69.0¡16.3
DL,CO % pred 44.5¡16.2 46.2¡15.3 44.9¡14.8 48.0¡16.1 46.6¡15.6
CPI 53.2¡12.4 51.8¡11.7 52.8¡11.2 50.7¡12.1 51.6¡11.7
Data are presented as mean¡SD, n (%) or median (95% CI), unless otherwise stated. HRCT: high-resolution computed tomography; FEV1: forced expiratory volume in
1 s; % pred: % predicted; FVC: forced vital capacity: DL,CO: diffusing capacity of the lung for carbon monoxide; CPI: composite physiologic index.
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CPFE is prevalent
CPFE was common in our cohort. Of the 169 patients with HRCT
scans in the 6-month analysis, 86 (51%) had evidence of
emphysema, 42 (25%) with moderate or severe emphysema. In
the 12-month analysis, 55 (47%) of the 118 patients with HRCT
had CPFE, 32 (27%) moderate or severe. The moderate/severe
combined emphysema patients tended to have higher FEV1, FVC
and lower CPI with equivocal DL,CO, than those with none/mild
emphysema (table 4). The mean FEV1/FVC ratios in the none/
mild emphysema groups were 0.84–0.85, higher than those in the
moderate/severe emphysema group (0.78–0.79); however, all
were greater than the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) criteria for obstruction (0.70) [22].
CPFE and survival
A longitudinal decline in FEV1 was the strongest and most
consistent predictor of mortality for patients with moderate-to-
severe emphysema on HRCT (table 5). In contrast, change in
FVC, DL,CO and CPI were not predictive at 12 months follow-up
and only FVC was predictive at 6 months. Furthermore, the HR
associated with a 10% decline in FEV1 increased for increasing
levels of emphysema on HRCT. The HR (95% CI) increased from
1.8 (0.8–4.1) to 2.5 (1.2–5.1) to 3.7 (1.0–13.7) in patients with no
emphysema, none/mild emphysema and moderate/severe
emphysema, respectively. Cox survival curves are shown in
figure 2e–h.
In the none/mild emphysema group, a five-point increase in
the CPI appeared to be the best predictor with the highest HR
(95% CI) at 12 months (3.6 (1.7–7.7); p50.001) (table 5).
12-month relative declines in DL,CO and FVC performed
similarly with HRs of 2.9 and 2.8, respectively. In a separate
12-month analysis of patients with no emphysema, a five-point
increase in CPI out performed the other measures with a HR of 4.4
(1.8–10.7) compared with relative declines in DL,CO 2.8 (1.3–4.4)
and FVC 2.6 (0.8–2.6).
Overall, grouping patients by emphysema status increased
each pulmonary function model’s IOC, therefore knowing
emphysema status provided the best mortality prediction.
DISCUSSION
In a large cohort of patients with IPF we described that:
1) baseline individual pulmonary function parameters (FEV1,
FVC or DL,CO) and the CPI were predictive of subsequent
mortality; 2) an increase in CPI of at least five points over 6 or
12 months significantly predicted mortality and was, therefore,
clinically relevant; 3) longitudinal changes in DL,CO and CPI
are more predictive than FVC and FEV1, and comparable to
each other; 4) CPFE is common in patients diagnosed with IPF;
5) longitudinal change in FEV1 was most predictive of mor-
tality in patients with CPFE; and 6) CPI may be the best
predictor in patients without emphysema. These data confirm
the value of longitudinal physiological monitoring in IPF
patients but extend previous results to highlight the impor-
tance of accounting for the presence and severity of emphy-
sema in choosing the optimal longitudinal measure of
physiological derangement to predict outcome.
Comparison of CPI and individual measures of pulmonary
function
Without accounting for emphysema, baseline PFT measure-
ments and CPI were all predictive of mortality. The baseline
DL,CO and CPI were the best predictors and were similar,
which is not entirely consistent with an article describing CPI
[18]. In a study by WELLS et al. [18] and a follow-up study by
LATSI et al. [10], which incorporated longitudinal changes in
patients with UIP and nonspecific interstitial pneumonia, the
baseline CPI was reported to be a better predictor for mortality
than baseline DL,CO. These differences could be due to
differences in patient population or sample size with .200
additional cases of IPF in this dataset.
To compare CPI as a longitudinal predictor, we identified the
magnitude of CPI change that increases risk of subsequent
mortality, a CPI increase of at least five points at 6 or
12 months follow-up. Although extreme worsening of CPI
was associated with an even higher risk of mortality, the small
numbers of patients with these severe changes made those cut-
off points impractical. Importantly, a recent report from the
IFIGENIA (Idiopathic Pulmonary Fibrosis International Group
Exploring N-acetyl-cysteine I Annual) study group demon-
strated a difference of 5.47 in CPI in placebo-treated patients
compared with a change of 0.509 in N-acetylcysteine-treated
patients [23]. This finding suggests broad applicability of the
cut-off point of five; however, there were too few deaths in the
study to examine the relationship of this increase on mortality.
An increase in CPI of at least five points remained a significant
predictor of mortality even when patients whose CPI wor-
sened by .15 were removed highlighting that an increase of
TABLE 2 Hazard ratios (HRs) for mortality associated with
discrete differences in 321 baseline individual
pulmonary function tests and composite
physiology index
HR (95% CI)# p-value
Difference in FEV1 % pred
5% less 1.1 (1.0–1.1) 0.015
10% less 1.1 (1.0–1.2) 0.015
15% less 1.2 (1.0–1.3) 0.015
Difference in FVC % pred
5% less 1.1 (1.0–1.1) 0.003
10% less 1.2 (1.1–1.3) 0.003
15% less 1.2 (1.1–1.4) 0.003
Difference in DL,CO % pred
5% less 1.1 (1.1–1.2) ,0.001
10% less 1.2 (1.1–1.4) ,0.001
15% less 1.4 (1.2–1.6) ,0.001
Difference in CPI
5 points more 1.2 (1.1–1.2) ,0.001
10 points more 1.3 (1.2–1.5) ,0.001
15 points more 1.6 (1.3–1.9) ,0.001
FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital
capacity; DL,CO: diffusing capacity of the lung for carbon monoxide; CPI:
composite physiologic index. #: HRs are based on Cox models that assume a
continuous change in each value. The hazards have been tabulated at clinically
relevant differences. For example, a patient with a baseline FVC 10% less than
another patient has a 20% increased hazard (HR 1.2).
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five in CPI is significant and not just driven by the subset of
patients with extreme worsening.
Throughout our study the DL,CO and CPI were comparable
predictors both at baseline and longitudinally. The FVC was as
strong as DL,CO at 12 months. Median survival discrimination
between these three predictors was comparable. In summary,
these analyses suggest that contrary to our hypothesis, in all-
comers with IPF, longitudinal change in either FVC or DL,CO
appear equivalent to changes in CPI. However, when patients with
emphysema are removed, CPI appears to be a better predictor.
Impact of CPFE
Prior studies highlight that longitudinal changes in FVC and
DL,CO are important but imperfect predictors of subsequent
mortality [2, 7, 8, 10, 24]. This imperfection could be due to
concomitant emphysema. In our cohort, combined moderate-
to-severe emphysema was seen in one quarter of our IPF
patients with HRCT, any emphysema was seen in half of the
patients. Grouping patients by emphysema status improved
the ability of the models to predict mortality by IOC analysis.
These results argue that CPFE is common, and identifying
CPFE is important in clarifying the appropriate prognostic
measure. However, identifying patients with CPFE does not
appear to be feasible with spirometry alone. Our patients with
moderate/severe emphysema did not have FEV1/FVC ratios
consistent with obstruction as per the GOLD criteria [22]. Less
than half (42.6%) of CPFE patients from one study met GOLD
criteria for chronic obstructive pulmonary disease [25]. There-
fore, accurately diagnosing CPFE may require HRCT.
The differential ability of individual measures of pulmonary
function to predict mortality based on the quantity of emphy-
sema is a novel and important finding of our study. Our
hypothesis predicted that CPI would be the strongest predictor
of mortality in patients with CPFE. However, our data high-
light that change in FEV1 appeared to be the best surrogate for
predicting subsequent mortality in IPF patients with moderate-
to-severe emphysema. Interestingly, the HRs associated with
declining FEV1 increased with increasing emphysema on
HRCT scan in a dose-dependent fashion. FEV1 was not a
significant predictor in the patients without emphysema just as
changes in FVC, DL,CO or CPI at 12 months were not con-
sistently predictive of subsequent mortality in patients with
moderate/severe emphysema.
In our dataset, patients who had a decline in FVC over time
almost always had a decline in FEV1 as well. This fact under-
scores why CPI may not be an effective longitudinal measure
in CPFE, since FEV1 and FVC have opposite effects on the CPI:
a lower FEV1 decreases the CPI, a lower FVC increases it.
Therefore, the CPI may remain balanced in the face of pro-
gressive obstruction and restriction. More surprising, the
DL,CO did not statistically predict mortality in the emphysema
patients which may be due to selection bias as more severely ill
patients may not be able to perform a DL,CO test or increased
survivorship in a small number of patients. The Cox survival
curves show good separation for 4–5 yrs for both CPI and
DL,CO with more separation for DL,CO, but come back together
with increased survivorship in a small sample.
TABLE 3 Longitudinal hazard ratios (HR) for mortality by absolute increase in composite physiologic index (CPI) and relative
decrease in individual pulmonary function tests over 6 and 12 months
6-month change# 12-month change"
n (%) HR (95% CI) p-value n (%) HR (95% CI) p-value
Decline in FEV1 % pred
5 81 (38) 1.6 (1.1–2.3) 0.018 72 (50) 2.3 (1.4–3.7) ,0.001
10 44 (21) 1.6 (1.0–2.4) 0.051 42 (29) 2.2 (1.3–3.5) 0.002
15 24 (11) 1.6 (0.9–2.8) 0.086 25 (17) 2.1 (1.3–3.6) 0.005
20 8 (4) 1.4 (0.6–3.5) 0.473 9 (6) 3.6 (1.6–8.1) 0.001
Decline in FVC % pred
5 88 (42) 1.8 (1.2–2.7) 0.002 75 (52) 1.8 (1.1–2.9) 0.012
10 51 (24) 1.4 (0.9–2.1) 0.122 51 (35) 2.4 (1.5–3.8) ,0.001
15 28 (13) 1.1 (0.6–1.8) 0.857 26 (18) 2.6 (1.6–4.5) ,0.001
20 12 (6) 2.0 (1.0–4.0) 0.051 15 (10) 3.6 (1.9–6.9) ,0.001
Decline in DL,CO % pred
10 74 (35) 1.7 (1.1–2.5) 0.011 68 (47) 2.2 (1.4–3.5) 0.001
15 51 (24) 1.6 (1.1–2.5) 0.029 57 (40) 2.3 (1.5–3.7) ,0.001
20 33 (16) 1.8 (1.1–3.0) 0.030 37 (26) 3.0 (1.8–4.9) ,0.001
25 20 (9) 2.3 (1.2–4.2) 0.010 26 (18) 3.5 (2.0–6.1) ,0.001
Increase in CPI
+5 51 (24) 1.7 (1.1–2.7) 0.019 63 (44) 2.1 (1.3–3.5) 0.004
+10 20 (9) 1.3 (0.7–2.4) 0.439 21 (15) 2.3 (1.2–4.2) 0.011
+15 4 (2) 2.0 (0.6–6.6) 0.240 9 (6) 3.3 (1.4–7.7) 0.007
+20 2 (1) 1.2 (0.2–8.4) 0.884 2 (1) 5.2 (1.1–23.8) 0.036
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; DL,CO: diffusing capacity of the lung for carbon monoxide. #: n5211; ": n5144.
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FIGURE 2. Cox model survival estimates for relevant 12 month longitudinal changes in pulmonary function tests or composite physiologic index (CPI) in all patients with
a–d) idiopathic pulmonary fibrosis (IPF) and e–h) combined IPF and moderate/severe emphysema. a, e) A relative decline in forced expiratory volume in 1 s (FEV1) %
predicted of .10% (– – – – –) versus ,10% (–––––), followed by b, f) a relative decline in forced vital capacity (FVC) % pred of .10% (– – – – –) versus ,10% (–––––). c, g) A
relative decrease in diffusing capacity of the lung for carbon monoxide (DL,CO) % pred of 15% (– – – – – ) versus a ,15% change (–––––). d, h) An absolute CPI increase .5
points (– – – – – ) versus ,5 points (–––––). Survival is dated from the time of their last analysed pulmonary function test (PFT), the 12 month study. Therefore, this survival
applies to patients able to survive 1 yr from their baseline study. These physiologic cut-off points were chosen based on prior literature and the best prognostic fit according to
index of concordance. All Cox models are adjusted for the baseline average PFT or CPI value, average age at diagnosis of 62 yrs, male sex and positive smoking history, with
baseline hazards stratified by whether the patient was in the stable or change group.
S.L. SCHMIDT ET AL. PULMONARY FIBROSIS
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 38 NUMBER 1 181
Limitations
Important limitations of this study include the possibility of
selection or referral bias, the absence of data to assess
for concomitant pulmonary hypertension and the lack of
prospectively defined treatments which precludes our ability
to evaluate any potential impact of treatment on outcome. The
lack of available HRCT in all patients could lead to selection
bias. However, our subset of patients with HRCT scans had
TABLE 4 Demographics of patients stratified by presence and severity of combined pulmonary fibrosis and emphysema
6-month analysis 12-month analysis
None/mild Moderate/severe None/mild Moderate/severe
Patients n 127 42 86 32
Age at diagnosis yrs 63.8¡9.9 64.0¡9.6 62.8¡10.1 62.6¡9.8
Male 94 (74.0) 33 (78.6) 65 (75.6) 23 (71.9)
Ever tobacco use 89 (70.1) 42 (100) 57 (66.3) 32 (100)
Tobacco pack-yrs 21.0¡25.0 46.4¡28.4 20.8¡25.8 45.4¡26.5
Surgical lung biopsy 98 (77.2) 20 (47.6) 71 (82.6) 17 (53.1)
Follow-up yrs 5.1 (4.7–6.1) 5.3 (3.3–7.9) 5.3 (5.0–7.0) 6.0 (2.5–6.8)
HRCT type
Volumetric 35 (27.6) 16 (38.1) 17 (19.8) 9 (28.1)
Incremental 91 (71.1) 26 (61.9) 69 (80.2) 23 (71.9)
Emphysema
None 83 (65.4) 63 (73.3)
Mild 44 (34.6) 23 (26.7)
Moderate 32 (76.2) 27 (84.4)
Severe 10 (23.8) 5 (15.6)
Pulmonary function
FEV1 % pred 77.4¡16.9 84.0¡16.2 78.1¡17.4 88.5¡19.6
FVC % pred 64.8¡14.3 76.2¡15.2 65.3¡14.8 79.2¡16.1
FEV1/FVC ratio 0.84¡0.06 0.78¡0.07 0.85¡0.05 0.79¡0.07
DL,CO % pred 45.8¡14.3 42.2¡16.0 46.7¡15.8 46.3¡15.3
CPI 53.2¡10.8 51.7¡12.5 52.6¡11.7 49.1¡11.5
Data are presented as mean¡SD, n (%) or median (95% CI), unless otherwise stated. HRCT: high-resolution computed tomography; FEV1: forced expiratory volume in
1 s; % pred: % predicted; FVC: forced vital capacity; DL,CO: diffusing capacity of the lung for carbon monoxide; CPI: composite physiologic index.
TABLE 5 Longitudinal hazard ratios (HRs) for mortality associated with absolute increases in composite physiologic index (CPI)
and relative decreases in individual pulmonary function tests over 6 and 12 months in patients with combined
pulmonary fibrosis and emphysema
6-month change 12-month change
n (%) HR (95% CI) p-value n (%) HR (95% CI) p-value
None-to-mild empysema#
10% decline FEV1 31 (24.4) 1.4 (0.8–2.6) 0.268 26 (30.2) 2.5 (1.2–5.1) 0.012
10% decline FVC 36 (28.3) 1.4 (0.8–2.6) 0.209 29 (33.7) 2.8 (1.4–5.9) 0.005
15% decline DL,CO 31 (24.4) 2.4 (1.3–4.4) 0.005 33 (38.4) 2.9 (1.4–5.7) 0.003
+5 increase CPI 33 (26.0) 2.4 (1.3–4.4) 0.003 34 (39.5) 3.6 (1.7–7.7) 0.001
Moderate-to-severe emphy-
sema"
10% decline FEV1 4 (9.5) 8.4 (1.9–37.8) 0.006 6 (18.8) 3.7 (1.0–13.7) 0.046
10% decline FVC 5 (11.9) 4.1 (1.2–14.0) 0.025 9 (28.1) 2.1 (0.8–6.0) 0.154
15% decline DL,CO 13 (31.0) 2.1 (0.8–5.5) 0.140 12 (37.5) 2.1 (0.7–6.0) 0.174
+5 increase CPI 11 (26.2) 1.9 (0.6–5.7) 0.279 15 (46.8) 2.4 (0.8–7.9) 0.135
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; DL,CO: diffusing capacity of the lung for carbon monoxide. #: n5127 for 6-month change and n5 86 for
12-month change; ": n542 for 6-month change and n532 for 12-month change.
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similar clinical characteristics to the remainder of the cohort,
theoretically lessening the chance that only patients with
emphysema had HRCT scans available for analysis. Also, our
CPFE patient population is similar to cohorts previously
described in terms of baseline FEV1 and DL,CO. Our patients
tended to have a lower FVC and there was a higher percen-
tage of females [25–27]. Another limitation is the lack of a
computer-generated quantitative score for the HRCT scans.
The available HRCT scans spanned many years during which
significant advancements were made in HRCT technology.
Further prospective, quantitative HRCT information on IPF
patients could provide refinement to this analysis and extend
these findings. Other limitations include referral bias as
complicated cases with dual diagnoses may be more likely to
be referred. We do not have systematic data in the CPFE cohort
to control for pulmonary hypertension or treatments received
in the survival analyses. Therefore, we cannot reflect on the
significance that known pulmonary hypertension or a parti-
cular chronic obstructive pulmonary disease phenotype may
have in an individual patient. Also, the most consistent longi-
tudinal findings occur at 12-month follow-up PFT. Therefore
applying our results would require that a patient be alive and
able to perform the testing at 12 months.
In a large, well characterised cohort of patients with IPF an
increase in CPI of at least five points is a meaningful predictor
of subsequent mortality. Longitudinal changes in CPI were
comparable to changes in FVC and DL,CO unless emphysema
was absent wherein CPI was superior. Combined pulmonary
fibrosis and emphysema is common in patients diagnosed with
IPF. FEV1 appears to be the best physiological predictor of
mortality in CPFE.
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